NewAmsterdam Pharma Company N.V.

NAMS

$25.59

+2.69%

N/A+$0.67

Healthcare

Biotechnology

NASDAQ

Active Trading

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing ...

Historical Employee Count of NAMS

Current

100

Change

+47.06%

Minimum

Maximum

100

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	100	10-K	Feb 18, 2026	View
Dec 31, 2024	68	10-K	Feb 26, 2025	View
Dec 31, 2023	29	10-K	Feb 28, 2024	View
Dec 31, 2022	17	20-F	Mar 31, 2023	View
Nov 22, 2022	17	20-F	Nov 28, 2022	View

Supply Chain of NAMS

Upstream / Downstream / Proxies

Upstream

Piramal Pharma Solutions (Piramal Pharma Ltd)NSE:PPLPHARMAUnnamed CDMO (Canada-based)Unnamed CDMO (Austria-based)Unnamed CDMO (US-based, not Piramal)API Raw Material Suppliers (via Piramal Pharma Solutions network)Ezetimibe API Suppliers (generic drug substance)

Downstream

A. Menarini International Licensing S.A. (Menarini Group)Menarini Group (EU Distribution Network)US Market (Direct Commercialization – Planned)Japan Partner (Phase 2 Study Initiated)

Proxies

Piramal Pharma LtdNSE:PPLPHARMAAmgen Inc.NASDAQ:AMGN Esperion Therapeutics Inc.NASDAQ:ESPR Novartis AGNYSE:NVS

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer